Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy.
Services
Services
Date issued
2011Journal title
BREAST CANCER RESEARCH
Type of content
Publicación de congreso
